Review
Oncology
Christian M. Vonk, Adil S. A. Al Hinai, Diana Hanekamp, Peter J. M. Valk
Summary: Although most AML patients achieve CR after initial induction chemotherapy, residual leukemic cells may lead to relapse, with MRD serving as a prognostic marker. Molecular techniques like NGS offer a sensitive assessment of MRD markers, but face challenges such as limited sensitivity/specificity and difficulty in distinguishing mutations. Multiple studies have explored the association between MRD detection by molecular assays and AML relapse, highlighting limitations, challenges, and opportunities.
Review
Oncology
Marisa J. L. Aitken, Farhad Ravandi, Keyur P. Patel, Nicholas J. Short
Summary: Quantification of measurable residual disease (MRD) provides critical prognostic information in acute myeloid leukemia (AML), with different detection platforms having varying sensitivity and applicability. MRD negativity is associated with reduced risk of relapse in AML, but the therapeutic implications remain unclear and require further investigation.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Article
Oncology
Zhiheng Cheng, Yifeng Dai, Wenhui Huang, Qingfu Zhong, Pei Zhu, Wenjuan Zhang, Zhihua Wu, Qing Lin, Huoyan Zhu, Longzhen Cui, Tingting Qian, Cong Deng, Lin Fu, Yan Liu, Tiansheng Zeng
Summary: The study indicates that high expression of miR-20b is a poor prognostic indicator for AML, but allogeneic hematopoietic stem cell transplantation (allo-HSCT) may override its prognostic impact.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Kritika Srinivasan Rajsri, Nainita Roy, Sohini Chakraborty
Summary: Acute myeloid leukemia (AML) is a blood cancer characterized by immature blood cells called leukemic blasts. Leukemia stem cells (LSCs) are resistant to chemotherapy and can cause disease relapse. Understanding the molecular basis of LSCs is important in identifying and targeting these cells for more effective treatment.
Article
Oncology
Ding Li, Jiaming Liang, Wei Yang, Wenbin Guo, Wenping Song, Wenzhou Zhang, Xuan Wu, Baoxia He
Summary: This study explores the clinical value of lipid metabolism reprogramming in AML and develops a risk signature with six lipid metabolism-related genes. The signature has independent prognostic value in AML patients and is closely related to the immune landscape and immunotherapy response.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Lisa Weijler, Florian Kowarsch, Matthias Woedlinger, Michael Reiter, Margarita Maurer-Granofszky, Angela Schumich, Michael N. Dworzak
Summary: Acute myeloid leukemia (AML) is the second most common and aggressive type of leukemia in children and adolescents. Flow cytometry is an effective method to monitor the number of remaining leukemic cells in the bone marrow of AML patients, but the data patterns are complex and difficult to identify. An automatic assessment approach using a semi-supervised machine learning model has been developed to address these challenges.
Article
Oncology
Tianqi Liang, Zhiyong Peng, Chunfu Li, Junbin Huang, Huabin Wang, Chaoke Bu, Jian Li, Yongzhi Zheng, Xiaoqin Feng, Huiping Li, Chun Chen
Summary: This study evaluated the prognostic value of CD56 in childhood AML and found that CD56 is associated with poor prognosis in specific groups of patients. This suggests that CD56 may be an important factor in risk stratification for AML.
Article
Biochemistry & Molecular Biology
Simona Pagliuca, Carmelo Gurnari, Keman Zhang, Tariq Kewan, Waled Bahaj, Minako Mori, Ishani Nautiyal, Marie Therese Rubio, Francesca Ferraro, Jaroslaw P. Maciejewski, Li Wang, Valeria Visconte
Summary: V-domain Ig suppressor of T-cell activation (VISTA) is a critical negative regulator of antitumor immune response. In this study, the researchers explored the role of VISTA in the generation of an immune escape environment in acute myeloid leukemia (AML) patients. They found that VISTA expression levels were correlated with AML cell differentiation, NPM1 mutations, and disease recurrence.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemical Research Methods
Pedro Casado, Pedro R. Cutillas
Summary: Acute myeloid leukemia (AML) is a heterogeneous cancer with no cure, and current therapies have limited success due to disease complexity. Proteomics and phosphoproteomics studies provide insights into AML biology and potential biomarkers and drug targets. The use of these approaches can contribute to the development of precision medicine for AML patients.
MOLECULAR & CELLULAR PROTEOMICS
(2023)
Review
Medicine, General & Internal
Davide Lazzarotto, Anna Candoni
Summary: Monitoring Minimal Residual Disease (MRD) is crucial in acute myeloid leukemia (AML) for guiding treatment, determining the need for stem cell transplantation, and detecting relapse early. However, more than 50% of AML patients lack specific molecular markers for MRD monitoring. This review focuses on the use of WT1 overexpression as an MRD marker in AML patients undergoing intensive chemotherapy, including stem cell transplantation. The standardized method of European LeukemiaNet is recommended for achieving optimal sensitivity and specificity.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Oncology
Eleonora Boscaro, Irene Urbino, Federica Maria Catania, Giulia Arrigo, Carolina Secreto, Matteo Olivi, Stefano D'Ardia, Chiara Frairia, Valentina Giai, Roberto Freilone, Dario Ferrero, Ernesta Audisio, Marco Cerrano
Summary: Several factors, including patient-related factors, AML manifestations at diagnosis, and disease genetics, are crucial in accurately estimating AML prognosis. However, the rapidly evolving field and the availability of MRD data have made traditional prognostic factors less reliable. This review summarizes established and new AML risk factors and discusses emerging comprehensive approaches to integrate relevant prognostic data.
Article
Oncology
Muhammad Umair Mushtaq, Alexandra M. Harrington, Sibgha Gull Chaudhary, Laura C. Michaelis, Karen-Sue B. Carlson, Sameem Abedin, Lyndsey Runass, Natalie S. Callander, Michael J. Fallon, Mark Juckett, Aric C. Hall, Peiman Hematti, Ryan J. Mattison, Ehab L. Atallan, Guru Subramanian Guru Murthy
Summary: In patients with relapsed or refractory AML, salvage chemotherapy with CLAG-M was associated with higher complete remission rates, MRD negativity, and improved overall survival when followed by transplant.
LEUKEMIA & LYMPHOMA
(2021)
Article
Oncology
Pian Li, Junjun Li, Feng Wen, Yixiong Cao, Zeyu Luo, Juan Zuo, Fei Wu, Zhiqin Li, Wenlu Li, Fujue Wang
Summary: In this study, a cuproptosis-related lncRNA signature was constructed to predict the prognosis and inform potential therapeutic strategies for acute myeloid leukemia (AML) patients. The signature was based on the analysis of RNA-seq and clinical data, and showed promising prognostic value and predictive power.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Wei Cui, Yuna Liu, Yanan Tan, Xingyue Peng, Longzhen Cui, Zhiheng Cheng, Yifeng Dai, Lin Fu, Tiansheng Zeng, Yan Liu
Summary: The study found that high HMGN2 expression is associated with longer survival in acute myeloid leukemia, while high HMGN5 expression is associated with shorter survival, indicating a potential prognostic indicator for AML.
Article
Hematology
Abhishek Maiti, Courtney D. DiNardo, Sa A. Wang, Jeffrey Jorgensen, Tapan M. Kadia, Naval G. Daver, Nicholas J. Short, Musa Yilmaz, Naveen Pemmaraju, Gautam Borthakur, Prithviraj Bose, Ghayas C. Issa, Alessandra Ferrajoli, Elias J. Jabbour, Nitin Jain, Guillermo Garcia-Manero, Maro Ohanian, Koichi Takahashi, Guillermo Montalban-Bravo, Lucia Masarova, Jan A. Burger, Philip A. Thompson, Srdan Verstovsek, Koji Sasaki, Michael Andreeff, Caitlin R. Rausch, Kathryn S. Montalbano, Sherry Pierce, Wei Qiao, Jing Ning, Hagop M. Kantarjian, Marina Y. Konopleva, Farhad Ravandi
Summary: Assessment of measurable residual disease (MRD) provides prognostic information in acute myeloid leukemia (AML). However, it remains unclear how MRD status impacts survival outcomes in older/unfit patients receiving first-line therapy with 10-day decitabine and venetoclax. This study found that achieving a negative MRD at 1, 2, and 4 months post-treatment significantly improved survival in this patient population.
Article
Hematology
Elise Sourdeau, Ludovic Suner, Mara Memoli, Alexis Genthon, Frederic Feger, Lou Soret, Nassera Abermil, Laurence Heuberger, Chrystele Bilhou-Nabera, Helene Guermouche, Fabrizia Favale, Simona Lapusan, Michael Chaquin, Claire Hirschauer, Mohamad Mohty, Ollivier Legrand, Francois Delhommeau, Pierre Hirsch
Summary: Chemotherapy resistance is the main cause of treatment failure in acute myeloid leukemia (AML) and is related to ATP-binding cassette transporter activity. This study investigates the relationships between ABC activity, immunophenotypic, cytogenetic, molecular, and targeted next-generation sequencing features in AML patients. High ABC activity is associated with certain characteristics (less proliferating disease, immature immunophenotype, gene mutations defining secondary-type AML), while low ABC activity is associated with different characteristics (more mature myeloid differentiation, monocytic commitment, certain gene mutations defining de novo-type AML). ABC activity can be used to predict AML ontogeny and may be an independent factor for event-free survival when considered with full molecular data.
Letter
Hematology
Michele Wieczorek, Myriam Labopin, Luca Castagna, Eolia Brissot, Gerard Socie, Anna Maria Raiola, Emanuele Angelucci, Arancha Bermudez Rodriguez, Ibrahim Yakoub-Agha, Mahmoud Aljurf, Charles Crawley, Jean Baptiste Mear, Maurizio Musso, Renato Fanin, Daniele Avenoso, Pascal Turlure, Cristina Tecchio, Jaime Sanz, Fabio Ciceri, Arnon Nagler, Mohamad Mohty
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Oncology
Romain Lannes, Mehmet Samur, Aurore Perrot, Celine Mazzotti, Marion Divoux, Titouan Cazaubiel, Xavier Leleu, Anais Schavgoulidze, Marie-Lorraine Chretien, Salomon Manier, Didier Adiko, Frederique Orsini-Piocelle, Francois Lifermann, Sabine Brechignac, Lauris Gastaud, Didier Bouscary, Margaret Macro, Alice Cleynen, Mohamad Mohty, Nikhil Munshi, Jill Corre, Herve Avet-Loiseau
Summary: Using single-cell genomics, it was found that high-risk events in multiple myeloma (MM) patients are often missed at diagnosis and only selected at relapse. This suggests the need for more aggressive treatment at diagnosis to prevent these aggressive cells from becoming dominant clones.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Editorial Material
Hematology
Mohamad Mohty, Florent Malard
Summary: This study evaluated the safety and efficacy of a novel recombinant human interleukin-22 (IL-22) dimer in combination with systemic corticosteroids for the treatment of newly diagnosed gastrointestinal acute graft-versus-host disease (GVHD). The results showed that the overall response rate of the treatment group at day 28 was 70%.
Article
Biophysics
Giuliano Filippini Velazquez, Myriam Labopin, Johanna Tischer, Anna Maria Raiola, Emanuele Angelucci, Alexander D. Kulagin, Piero Galieni, Arancha Bermudez, Claude-Eric Bulabois, Nicolaus Kroeger, Jose Luis Diez-Martin, Mi Kwon, Arnon Nagler, Christoph Schmid, Fabio Ciceri, Mohamad Mohty
Summary: HAPLO-SCT2 is a viable option for acute leukaemia relapse after HAPLO-SCT1, with comparable engraftment, toxicity, risk factors, and long-term outcome to allo-SCT2 in a matched donor setting. A retrospective registry analysis of 82 adult patients showed a 2-year overall survival/leukaemia-free survival of 34.3%/25.4% and a 2-year non-relapse mortality/relapse incidence of 17.6%/57%. The most frequent cause of death was leukaemia.
BONE MARROW TRANSPLANTATION
(2023)
Article
Biophysics
Riccardo Saccardi, Hein Putter, Dirk-Jan Eikema, Maria Paula Busto, Eoin McGrath, Bas Middelkoop, Gillian Adams, Marina Atlija, Francis Ayuketang Ayuk, Helen Baldomero, Yves Beguin, Rafael de la Camara, Angel Cedillo, Anna Maria Sureda Balari, Christian Chabannon, Selim Corbacioglu, Harry Dolstra, Rafael F. Duarte, Remy Dulery, Raffaella Greco, Andreu Gusi, Nada Hamad, Michelle Kenyon, Nicolaus Kroeger, Myriam Labopin, Julia Lee, Per Ljungman, Lynn Manson, Florence Mensil, Noel Milpied, Mohamad Mohty, Elena Oldani, Kim Orchard, Jakob Passweg, Rachel Pearce, Regis Peffault de Latour, Helene A. Poirel, Tuula Rintala, J. Douglas Rizzo, Annalisa Ruggeri, Carla Sanchez-Martinez, Fermin Sanchez-Guijo, Isabel Sanchez-Ortega, Marie Trnkova, David Valcarcel Ferreiras, Leonie Wilcox, Liesbeth C. de Wreede, John A. Snowden
Summary: From 2016, EBMT and JACIE developed an international risk-adapted benchmarking program for HSCT outcome. The program aims to assure quality and meet accreditation requirements for EBMT Centers. With input from previous experience, the program established criteria for patient and Center selection and a statistical model based on key clinical variables. The experience so far has shown the feasibility, acceptability, and reliability of the system, while also identifying limitations and future challenges.
BONE MARROW TRANSPLANTATION
(2023)
Review
Biophysics
Mohamad Mohty, Florent Malard, Ahmed S. Alaskar, Mahmoud Aljurf, Mutlu Arat, Peter Bader, Frederic Baron, Ali Bazarbachi, Didier Blaise, Eolia Brissot, Fabio Ciceri, Selim Corbacioglu, Jean-Hugues Dalle, Fiona Dignan, Anne Huynh, Michelle Kenyon, Arnon Nagler, Antonio Pagliuca, Zinaida Peric, Paul G. Richardson, Annalisa Ruggeri, Tapani Ruutu, Ibrahim Yakoub-Agha, Rafael F. Duarte, Enric Carreras
Summary: Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life-threatening complication that can occur after hematopoietic cell transplantation (HCT). The European Society for Blood and Marrow Transplantation (EBMT) has recently updated the definition and severity grading system for SOS/VOD in adult patients. The aim of this work is to provide an update on the diagnosis, severity assessment, pathophysiology, and treatment of SOS/VOD in adult patients.
BONE MARROW TRANSPLANTATION
(2023)
Letter
Oncology
Frederic Baron, Myriam Labopin, Johanna Tischer, Anna Maria Raiola, Jan Vydra, Didier Blaise, Patrizia Chiusolo, Friedrich Stoelzel, Renato Fanin, Patrice Chevallier, Arnon Nagler, Fabio Ciceri, Mohamad Mohty
Summary: A study on the association between the occurrence of GVHD and the relapse of AML in patients undergoing Haplo-HCT with PTCy-based GVHD prophylaxis found that while grade I acute GVHD was associated with better LFS, grade III-IV acute and extensive chronic GVHD were correlated with higher nonrelapse mortality and lower LFS.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Letter
Oncology
Yishan Ye, Myriam Labopin, Jia Chen, Zafer Gulbas, Xi Zhang, Yener Koc, Didier Blaise, Fabio Ciceri, Emmanuelle Polge, Mohamed Houhou, Lin Li, Yi Luo, Depei Wu, He Huang, Mohamad Mohty, Norbert-Claude Gorin
Summary: For haploidentical hematopoietic cell transplantation (HAPLO), non-first-degree (NFD) related donors can be considered as alternatives when first-degree (FD) related donors are not available. However, the effectiveness of these NFD related transplants remains uncertain.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Article
Oncology
Arnon Nagler, Myriam Labopin, Didier Blaise, Anna Maria Raiola, Lucia Lopez Corral, Stefania Bramanti, Simona Sica, Mi Kwon, Yener Koc, Jiri Pavlu, Alexander Kulagin, Alessandro Busca, Arancha Bermudez Rodriguez, Peter Remenyi, Christoph Schmid, Eolia Brissot, Jaime Sanz, Ali Bazarbachi, Sebastian Giebel, Fabio Ciceri, Mohamad Mohty
Summary: Comparing outcomes of adult patients with secondary acute myeloid leukemia (sAML) and de novo AML after non-T-depleted haploidentical stem cell transplant (HaploSCT) with post-transplant cyclophosphamide, no significant difference was observed in transplantation outcomes between the two groups.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Review
Oncology
Jean El-Cheikh, Nour Moukalled, Florent Malard, Ali Bazarbachi, Mohamad Mohty
Summary: With the improvement in cancer treatment, including multiple myeloma, the risk of cardiovascular disease in patients has significantly increased, especially in elderly patients and those with additional risk factors. The risk factors can be patient-, disease-, and/or therapy-related, and they impact survival negatively. About 7.5% of multiple myeloma patients experience cardiovascular events, with varied risks depending on patient characteristics and treatment used. Cardiac toxicities have been associated with immunomodulatory drugs, proteasome inhibitors, and other agents, highlighting the importance of comprehensive cardiac evaluation and surveillance strategies for early detection and management.
BLOOD CANCER JOURNAL
(2023)
Review
Immunology
Mohammad Hassan Hodroj, Iman Abou Dalle, Nour Moukalled, Jean El Cheikh, Mohamad Mohty, Ali Bazarbachi
Summary: The outcome of B-cell acute lymphoblastic leukemia has improved with multi-agent chemotherapy and immunotherapeutic agents. However, relapse post-transplant is still common. This review discusses strategies such as tyrosine kinase inhibitors, innovative agents, and cellular therapy to prevent and overcome relapse post allo-HCT in ALL patients.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Maria-Victoria Mateos, Sikander Ailawadhi, Luciano J. Costa, Shakira J. Grant, Lalit Kumar, Mohamad Mohty, Didem Aydin, Saad Z. Usmani
Summary: This study examined the influence of sociodemographic factors on disparities in outcomes for multiple myeloma patients. The results showed that increasing age and low socioeconomic status were associated with worse patient outcomes globally. In the US, men had worse outcomes while women and minority populations had poorer access to treatment.
BLOOD CANCER JOURNAL
(2023)
Article
Hematology
Molly C. Tokaz, Helen Baldomero, Andrew J. Cowan, Wael Saber, Hildegard Greinix, Mickey B. C. Koh, Nicolaus Kroeger, Mohamad Mohty, Sebastian Galeano, Shinichiro Okamoto, Naeem Chaudhri, Amado J. Karduss, Fabio Ciceri, Vergilio Antonio R. Colturato, Selim Corbacioglu, Alaa Elhaddad, Lisa M. Force, Cristobal Frutos, Andres Gomez-De Leon, Nada Hamad, Nelson Hamerschlak, Naya He, Aloysius Ho, Xiao-jun Huang, Ben Jacobs, Hee-Je Kim, Minako Iida, Leslie Lehmann, Regis Peffault de Latour, Mary-Elizabeth M. Percival, Martina Perdomo, Walid Rasheed, Kirk R. Schultz, Adriana Seber, Bor-Sheng Ko, Anderson Joao Simione, Alok Srivastava, Jeff Szer, William A. Wood, Yoshihisa Kodera, Arnon Nagler, John A. Snowden, Daniel Weisdorf, Jakob Passweg, Marcelo C. Pasquini, Anna Sureda, Yoshiko Atsuta, Mahmoud Aljurf, Dietger Niederwieser
Summary: Acute myeloid leukemia (AML) is a fast-progressing and historically challenging disease. Hematopoietic stem cell transplantation (HSCT) is the best treatment option for many patients, but access and utilization on a global scale are unclear. This study aimed to investigate the global use of HSCT in AML and identify areas of need. The study found that AML incidence has increased globally, as has the use of HSCT, particularly allogeneic HSCT. However, there are significant regional variations in HSCT utilization and practices, including differences in graft sources. Further research is needed to understand and address these disparities.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Hematology
Thomas G. Martin, Marcelo Capra, Mohamad Mohty, Kenshi Suzuki, Hang Quach, Michele Cavo, Philippe Moreau, Meletios Dimopoulos, Kwee Yong, Christina Tekle, Meredith C. Foster, Yvonne Barnes, Marie-Laure Risse, Joseph Mikhael
Summary: The role, timing, and impact of transplantation on further therapy after relapse in multiple myeloma (MM) are still being debated in the era of highly active novel agents. The impact of prior transplantation on treatment benefit from monoclonal antibodies in patients with relapsed/refractory MM (RRMM) is largely unknown. This subgroup analysis examined efficacy and safety in patients from the Phase 3 IKEMA study with and without previous transplantation.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)